Humira Biosimilar Under Review: Amgen, AbbVie Tango Time
This article was originally published in Scrip
Executive Summary
Amgen Inc. revealed on Jan. 25 the FDA had accepted the firm's 351(k) application for its biosimilar of AbbVie Inc.'s tumor necrosis factor blocker Humira (adalimumab).